Enhanced oral bioavailability and anticancer efficacy of fisetin by encapsulating as inclusion complex with HPβCD in polymeric nanoparticles

References

• Adhami VM, Syed DN, Khan N, et al. (2012). Dietary flavonoid fisetin: a novel dual inhibitor of PI3K/Akt and mTOR for prostate cancer management. Biochem Pharmacol 84:1277–81
   PubMed Web of Science ®Google Scholar
• Bhat TA, Nambiar D, Pal A, et al. (2012). Fisetin inhibits various attributes of angiogenesis in vitro and in vivo – implications for angioprevention. Carcinogenesis 33:385–93
   PubMed Web of Science ®Google Scholar
• Bothiraja C, Yojana BD, Pawar AP, et al. (2014). Fisetin-loaded nanocochleates: formulation, characterisation, in vitro anticancer testing, bioavailability and biodistribution study. Expert Opin Drug Deliv 11:17–29
   PubMed Web of Science ®Google Scholar
• Cheng J, Teply BA, Sherifi I, et al. (2007). Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials 28:869–76
   PubMed Web of Science ®Google Scholar
• Chou RH, Hsieh SC, Yu YL, et al. (2013). Fisetin inhibits migration and invasion of human cervical cancer cells by down-regulating urokinase plasminogen activator expression through suppressing the p38 MAPK-dependent NF-κB signaling pathway. PLoS One 8:e71983
   PubMed Web of Science ®Google Scholar
• de Araújo MV, Vieira EK, Silva LG, et al (2008). Sulfadiazine/hydroxypropyl-beta-cyclodextrin host-guest system: characterization, phase-solubility and molecular modeling. Bioorg Med Chem 16:5788–94
   PubMed Web of Science ®Google Scholar
• Dua F, Menga H, Xua K, et al. (2014). CPT loaded nanoparticles based on beta-cyclodextrin-grafted poly(ethylene glycol)/poly(l-glutamic acid) diblock copolymer and their inclusion complexes with CPT. Colloids Surf B: Biointerfaces 113:230–6
   PubMed Web of Science ®Google Scholar
• Gidwani B, Vyasa A. (2016). Formulation, characterization and evaluation of cyclodextrin-complexed bendamustine-encapsulated PLGA nanospheres for sustained delivery in cancer treatment. Pharm Dev Technol 21:161–71
   PubMed Web of Science ®Google Scholar
• Hu L, Zhang H, Song W, et al (2012). Investigation of inclusion complex of cilnidipine with hydroxypropyl-β-cyclodextrin. Carbohydr Polym 90:1719–24
   PubMed Web of Science ®Google Scholar
• Jang KY, Jeong SJ, Kim SH, et al. (2012). Activation of reactive oxygen species/AMP activated protein kinase signaling mediates fisetin-induced apoptosis in multiple myeloma U266 cells. Cancer Lett 319:197–202
   PubMed Web of Science ®Google Scholar
• Jeong D, Choi JM, Choi Y, et al. (2013). Complexation of fisetin with novel cyclosophoroase dimer to improve solubility and bioavailability. Carbohydr Polym 97:196–202
   PubMed Web of Science ®Google Scholar
• Jiang L, Li X, Liu L, et al. (2013). Thiolated chitosan-modified PLA-PCL-TPGS nanoparticles for oral chemotherapy of lung cancer. Nanoscale Res Lett 8:66
   PubMed Web of Science ®Google Scholar
• Joshi G, Kumar A, Sawant K. (2014). Enhanced bioavailability and intestinal uptake of Gemcitabine HCl loaded PLGA nanoparticles after oral delivery. Eur J Pharm Sci 60:80–9
   PubMed Web of Science ®Google Scholar
• Kang KA, Piao MJ, Hyun JW. (2015). Fisetin induces apoptosis in human nonsmall lung cancer cells via a mitochondria-mediated pathway. In Vitro Cell Dev Biol Anim 51:300–9
   PubMed Web of Science ®Google Scholar
• Kulhari H, Pooja D, Shrivastava S, et al. (2014). Peptide conjugated polymeric nanoparticles as a carrier for targeted delivery of docetaxel. Colloids Surf B Biointerfaces 117:166–73
   PubMed Web of Science ®Google Scholar
• Kulhari H, Pooja D, Singh MK, et al. (2015). Bombesin-conjugated nanoparticles improve the cytotoxic efficacy of docetaxel against gastrin-releasing but androgen-independent prostate cancer. Nanomedicine UK 10:2847–59
   PubMed Web of Science ®Google Scholar
• Liu M, Cao W, Sun Y, et al. (2014). Preparation, characterization and in vivo evaluation of formulation of repaglinide with hydroxypropyl-β-cyclodextrin. Int J Pharm 477:159–66
   PubMed Web of Science ®Google Scholar
• Madan J, Baruah B, Nagaraju M, et al. (2012). Molecular cycloencapsulation augments solubility and improves therapeutic index of brominated noscapine in prostate cancer cells. Mol Pharm 9:1470–80
   PubMed Web of Science ®Google Scholar
• Madan J, Gundala S, Baruah B, et al. (2014). Cyclodextrin complexes of reduced bromonoscapine in guar gum microspheres enhance colonic drug delivery. Mol Pharm 11:4339–49
   PubMed Web of Science ®Google Scholar
• Maurya BK, Trigun SK. (2016). Fisetin modulates antioxidant enzymes and inflammatory factors to inhibit aflatoxin-B1 induced hepatocellular carcinoma in rats. Oxid Med Cell Long 2016:1–9
   Web of Science ®Google Scholar
• Mudshinge SR, Deore AB, Patil S, et al. (2011). Nanoparticles: emerging carriers for drug delivery. Saudi Pharm J. 19:129–41
   PubMed Web of Science ®Google Scholar
• Noh EM, Park YJ, Kim JM, et al. (2015). Fisetin regulates TPA-induced breast cell invasion by suppressing matrix metalloproteinase-9 activation via the PKC/ROS/MAPK pathways. Eur J Pharmacol 764:79–86
   PubMed Web of Science ®Google Scholar
• Pooja D, Babu Bikkina DJ, Kulhari H, et al. (2014). Fabrication, characterization and bioevaluation of silibinin loaded chitosan nanoparticles. Int J Biol Macromol 69:267–73
   PubMed Web of Science ®Google Scholar
• Qiu N, Cheng X, Wang G, et al. (2014). Inclusion complex of barbigerone with hydroxypropyl-β-cyclodextrin: preparation and in vitro evaluation. Carbohydr Polym 101:623–30
   PubMed Web of Science ®Google Scholar
• Sah H, Thoma LA, Desu HR, et al. (2013). Concepts and practices used to develop functional PLGA-based nanoparticulate systems. Int J Nanomed 8:747–65
   PubMed Web of Science ®Google Scholar
• Seguin J, Brullé L, Boyer R, et al. (2013). Liposomal encapsulation of the natural flavonoid fisetin improves bioavailability and antitumor efficacy. Int J Pharm 444:146–54
   PubMed Web of Science ®Google Scholar
• Suh Y, Afaq FJJ, Mukhtar H. (2009). A plant flavonoid fisetin induces apoptosis in colon cancer cells by inhibition of COX2 and Wnt/EGFR/NF-kappaB-signaling pathways. Carcinogenesis 30:300–7
   PubMed Web of Science ®Google Scholar
• Tripathi R, Samadder T, Gupta S, et al. (2011). Anticancer activity of a combination of cisplatin and fisetin in embryonal carcinoma cells and xenograft tumors. Mol Cancer Ther 10:255–68
   PubMed Web of Science ®Google Scholar
• U.S. Pharmacopeial Convention. (2007). Organic volatile impurities/residual solvents. General Chapter 467. Available at: http://www.usp.org/usp-nf/official-text/accelerated-revision-process/accelerated-revision-history/general-chapter-organic-volatile
   Google Scholar
• Yang PM, Tseng HH, Peng CW, et al. (2011). Dietary flavonoid fisetin targets caspase-3-deficient human breast cancer MCF-7 cells by induction of caspase-7-associated apoptosis and inhibition of autophagy. Int J Oncol 40:469–78
   PubMed Web of Science ®Google Scholar
• Yi C, Zhang Y, Yu Z, et al. (2014). Melatonin enhances the anti-tumor effect of fisetin by inhibiting COX-2/iNOS and NF-κB/p300 signaling pathways. PLoS One 9:e99943
   PubMed Web of Science ®Google Scholar
• Zhang H, Firempong CK, Wang Y, et al. (2016). Ergosterol-loaded poly(lactide-co-glycolide) nanoparticles with enhanced in vitro antitumor activity and oral bioavailability. Acta Pharmacol Sin 37:834–44
   PubMed Web of Science ®Google Scholar
• Zhang JQ, Jiang KM, An K, et al. (2015). Novel water-soluble fisetin/cyclodextrins inclusion complexes: preparation, characterization, molecular docking and bioavailability. Carbohydr Res 418:20–8
   PubMed Web of Science ®Google Scholar
• Zhao L, Feng SS. (2010). Enhanced oral bioavailability of paclitaxel formulated in vitamin E-TPGS emulsified nanoparticles of biodegradable polymers: in vitro and in vivo studies. J Pharm Sci 99:3552–60
   PubMed Web of Science ®Google Scholar